{"id":155163,"date":"2023-01-11T08:23:20","date_gmt":"2023-01-11T14:23:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/01\/generative-ai-approach-unlocks-path-to-accelerated-antibody-drug-creation-for-novel-therapeutic-targets"},"modified":"2023-01-11T08:23:20","modified_gmt":"2023-01-11T14:23:20","slug":"generative-ai-approach-unlocks-path-to-accelerated-antibody-drug-creation-for-novel-therapeutic-targets","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/01\/generative-ai-approach-unlocks-path-to-accelerated-antibody-drug-creation-for-novel-therapeutic-targets","title":{"rendered":"Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/generative-ai-approach-unlocks-path-to-accelerated-antibody-drug-creation-for-novel-therapeutic-targets.jpg\"><\/a><\/p>\n<p>Even though the clinical efficacy of antibody-based therapeutics has been established, no methods that involve the de novo design of antibodies with wet lab validation are available.<\/p>\n<p><b>About the study<\/b><\/p>\n<p>A recent study, posted in the <em><a href=\"https:\/\/www.biorxiv.org\/content\/10.1101\/2023.01.08.523187v1\" rel=\"noopener\">bioRxiv<\/a>*<\/em> preprint server, used generative AI models to develop <em>de novo<\/em> design antibodies against three distinct targets in a zero-shot fashion. A zero-shot designing method involves designing an antibody to bind to an antigen without follow-up optimization. The newly designed process has been termed <em>de novo<\/em>, meaning proteins (antibodies) were designed from first principles or from scratch.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Even though the clinical efficacy of antibody-based therapeutics has been established, no methods that involve the de novo design of antibodies with wet lab validation are available. About the study A recent study, posted in the bioRxiv* preprint server, used generative AI models to develop de novo design antibodies against three distinct targets in a [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,6],"tags":[],"class_list":["post-155163","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-robotics-ai"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/155163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=155163"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/155163\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=155163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=155163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=155163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}